AstraZeneca boosts lung drug business with up to $2.1 bln Almirall deal

LONDON, July 30 (Reuters) - AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion to acquire the rights to lung drugs developed by Spain's Almirall.